TY - JOUR TI - Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial AU - Glueer, Claus-C AU - Marin, Fernando AU - Ringe, Johann D. AU - Hawkins, AU - Federico AU - Moericke, Ruediger AU - Papaioannu, Nikolaos AU - Farahmand, AU - Parvis AU - Minisola, Salvatore AU - Martinez, Guillermo AU - Nolla, Joan AU - M. AU - Niedhart, Christopher AU - Guanabens, Nuria AU - Nuti, Ranuccio and AU - Martin-Mola, Emilio AU - Thomasius, Friederike AU - Kapetanos, Georgios AU - and Pena, Jaime AU - Graeff, Christian AU - Petto, Helmut AU - Sanz, AU - Beatriz AU - Reisinger, Andreas AU - Zysset, Philippe K. JO - JOURNAL OF BONE AND MINERAL RESEARCH PY - 2013 VL - 28 TODO - 6 SP - 1355-1368 PB - Wiley SN - 0884-0431 TODO - 10.1002/jbmr.1870 TODO - BONE MINERAL DENSITY; BONE MICROSTRUCTURE; FINITE ELEMENT ANALYSIS; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; HIGH RESOLUTION QUANTITATIVE COMPUTED TOMOGRAPHY; MALE OSTEOPOROSIS; VERTEBRAL FRACTURE TODO - Data on treatment of glucocorticoid-induced osteoporosis (GIO) in men are scarce. We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for 3 months, and had an areal bone mineral density (aBMD) T-score 1.5 standard deviations. Subjects received 20g/d teriparatide (n=45) or 35mg/week risedronate (n=47) for 18 months. Primary objective was to compare lumbar spine (L1L3) BMD measured by quantitative computed tomography (QCT). Secondary outcomes included BMD and microstructure measured by high-resolution QCT (HRQCT) at the 12th thoracic vertebra, biomechanical effects for axial compression, anterior bending, and axial torsion evaluated by finite element (FE) analysis from HRQCT data, aBMD by dual X-ray absorptiometry, biochemical markers, and safety. Computed tomography scans were performed at 0, 6, and 18 months. A mixed model repeated measures analysis was performed to compare changes from baseline between groups. Mean age was 56.3 years. Median GC dose and duration were 8.8mg/d and 6.4 years, respectively; 39.1% of subjects had a prevalent fracture, and 32.6% received prior bisphosphonate treatment. At 18 months, trabecular BMD had significantly increased for both treatments, with significantly greater increases with teriparatide (16.3% versus 3.8%; p=0.004). HRQCT trabecular and cortical variables significantly increased for both treatments with significantly larger improvements for teriparatide for integral and trabecular BMD and bone surface to volume ratio (BS/BV) as a microstructural measure. Vertebral strength increases at 18 months were significant in both groups (teriparatide: 26.0% to 34.0%; risedronate: 4.2% to 6.7%), with significantly higher increases in the teriparatide group for all loading modes (0.005